Focus: Becton Dickinson is a $19.4B global medical devices and diagnostic systems company headquartered in Franklin Lakes, NJ, serving hospitals, clinical laboratories, and patients worldwide. With 50,000+ employees, BD is a market leader in infection prevention, diagnostic imaging, and drug delivery systems.
Profile data last refreshed 10h ago · AI intelligence enriched 1w ago
Hot — 1107 jobs added in 30d
Net +633 (1107 new, 474 removed). Aggressive expansion phase.
Recent layoff filing — 85 affected
Source: state DOL filings via Big Local News
BD offers financial stability and operational scale but carries elevated restructuring risk and limited drug development upside; best for manufacturing, supply chain, and commercial roles rather than therapeutic innovation careers.
Represents 100% of company revenue; generic oral rinse with established safety but declining market differentiation.
Help build intelligence for Becton Dickinson
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Becton Dickinson's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Surgical site antiseptic approaching generic competition; part of ChloraPrep franchise.
Formulation variant facing LOE in April 2027; minimal differentiation in crowded surgical prep market.
Tinted variant of ChloraPrep facing April 2027 LOE; incremental innovation with limited lifecycle extension potential.
Single-swabstick formulation in LOE approaching phase; faces generic competition.
Swab formulation approaching LOE; part of generics-vulnerable ChloraPrep portfolio.
Flagship ChloraPrep variant facing April 2027 LOE; core to infection prevention franchise with high generic replacement risk.
Single-use convenience formulation in LOE approaching phase; vulnerable to generic erosion.
Surgical scrub product approaching LOE; limited indication data; faces mature category competition.
Established surgical scrub in LOE approaching phase; generic entry imminent.
4 discontinued, 11 duplicate formulations not shown
Health Brief: Medical devices join Trump’s tariff bargain - The Washington Post
Health Brief: Medical devices join Trump’s tariff bargain The Washington Post
Becton Dickinson pledges $19 billion US investment in deal with government - Reuters
Becton Dickinson pledges $19 billion US investment in deal with government Reuters
Global healthcare companies invest billions to boost US presence - Reuters
Global healthcare companies invest billions to boost US presence Reuters
Here's Why You Should Retain BDX Stock in Your Portfolio for Now - TradingView
Here's Why You Should Retain BDX Stock in Your Portfolio for Now TradingView
Two global health firms plan layoffs in metro Phoenix - The Business Journals
Two global health firms plan layoffs in metro Phoenix The Business Journals
Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium - Yahoo Finance
Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Source: state DOL filings, aggregated via Big Local News
Multiple WARN filings within 12 months signal high restructuring risk; despite $19B government investment pledge, material workforce reductions are actively underway and likely to continue.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo